1. GPCR/G Protein
  2. Guanylate Cyclase

Vericiguat (Synonyms: BAY1021189)

Cat. No.: HY-16774 Purity: >98.0%
Handling Instructions

Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.

For research use only. We do not sell to patients.
Vericiguat Chemical Structure

Vericiguat Chemical Structure

CAS No. : 1350653-20-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 248 In-stock
2 mg USD 132 In-stock
5 mg USD 264 In-stock
10 mg USD 420 In-stock
50 mg USD 1140 In-stock
100 mg USD 1680 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Featured Recommendations

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.

In Vitro

Vericiguat (0.01 μM to 100 μM) stimulates recombinant sGC concentration dependently, by 1.7-fold to 57.6-fold. When combined with the NO donor diethylamine/nitric oxide complex (DEA/NO), vericiguat and DEA/NO have a synergistic effect on the enzyme activity over a wide range of concentrations. At highest concentrations of vericiguat (100 μM) and DEA/NO (100 nM), the specific activity of sGC is 341.6-fold above baseline. Vericiguat stimulates the sGC reporter cell line concentration dependently, with an EC50 of 1005±145 nM. Vericiguat inhibits phenylephrine-induced contractions of rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings concentration dependently, with IC50 values of 798, 692, and 3072 nM, respectively. Vericiguat inhibits the U46619-induced contractions of porcine coronary artery rings concentration dependently, with an IC50 of 956 nM[1].

In Vivo

Chronic oral treatment with 3 or 10 mg/kg vericiguat qd results in a significant attenuation of blood pressure increase during the course of the study. However, the overall rise of blood pressure increase is not halted in the 3 and 10 mg/kg treatment groups. Vericiguat treatment at 3 or 10 mg/kg leads to a significant reduction in kidney injury molecule Kim-1 and osteopontin expression which are used as biomarkers for renal injury and dysfunction. Vericiguat results in a significant and dose-dependent increase in survival rates. In the 3 and 10 mg/kg qd treatment groups, the rat survival rate is 70% and 90%, respectively, at the study end[1].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.3453 mL 11.7266 mL 23.4533 mL
5 mM 0.4691 mL 2.3453 mL 4.6907 mL
10 mM 0.2345 mL 1.1727 mL 2.3453 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Vericiguat is dissolved in a mixture of 10% DMSO and 90% saline.

Rats: Rat are randomly allocated to three study groups: placebo (control), 24 low dose, and 24 high dose (3 and 10 mg/kg per day, respectively, administered po by gavage qd). Blood pressure is measured via the tail-cuff method once before the start of the study (day 0) to exclude preexisting differences between the groups and on day 7, 14, and 21. Body weight and survival are assessed on day 1, 8, and 15 and at the study end. At the end of the study (day 22), all animals are anesthetized, blood is collected, and animals are sacrificed; blood is taken in order to assess plasma parameters, and the heart is dissected into the left and right ventricles and is weighed to assess potential heart hypertrophy. Creatinine, urea, and renin activity in plasma are determined after extraction[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight








Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥150 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: